Key Summary Points {#FPar1}
==================

**Why carry out this study?**The DUAL II Japan trial compared the efficacy and safety of IDegLira with degludec in Japanese patients with type 2 diabetes (T2D) uncontrolled on basal or premixed insulin therapyThe DUAL II Japan trial presented the opportunity for a post hoc analysis to examine the safety and efficacy of transitioning patients from a premixed regimen (containing both basal and bolus insulin components) to IDegLira**What was learned from the study?**In patients treated previously with premixed insulin, IDegLira initiation resulted in improved HbA~1C~ and weight lossThis is the first study to offer insight into the effectiveness and safety of switching patients from premixed insulin therapy to IDegLiraThis post hoc evaluation provides support for further investigation into switching treatment from premixed insulin to IDegLira in patients with T2D

Introduction {#Sec1}
============

Type 2 diabetes (T2D) is a chronic disease caused by insulin resistance and a decline in beta cell function. As a result of the progressive nature of T2D, many patients eventually require insulin therapy \[[@CR1]\]. Although basal and premixed insulin, in combination with oral agents, are established treatments for T2D, many patients treated with these agents fail to achieve adequate glycemic control \[[@CR2]\]. As such, when prandial control is needed for patients with progressed T2D, options are limited and often include high complexity regimens, such as basal--bolus treatment.

Insulin degludec/liraglutide (IDegLira)---a fixed-ratio combination of the basal insulin, insulin degludec (degludec) and the glucagon-like peptide 1 receptor agonist (GLP-1RA), liraglutide---is emerging as an effective once-daily treatment option for patients requiring insulin initiation/intensification. This single pen combination product provides the ability to control fasting plasma glucose and postprandial plasma glucose in a single injection, with reduced insulin dose and better weight management compared with basal insulin and even basal--bolus treatment \[[@CR3]--[@CR5]\]. Successful outcomes, including a mean HbA~1c~ below 7.0% (53 mmol/mol) at end of trial, have been demonstrated with IDegLira in the global phase 3 DUAL clinical trial program \[[@CR3], [@CR5]--[@CR13]\]. Recently, the DUAL VIII trial investigated the durability of IDegLira versus insulin glargine 100 units/mL (IGlar U100) \[defined as HbA~1c~ of 7.0% (53 mmol/mol) or higher at two consecutive visits from week 26\] and demonstrated that IDegLira had a longer durability than IGlar U100. Treatment needed to be intensified much sooner with IGlar U100 (approximately 1 year) compared with over 2 years with IDegLira \[[@CR13]\].

Data are needed to help healthcare providers choose therapy intensification in patients who are already on insulin therapies and have HbA~1c~ levels above treatment target. Often, one considered step is the use of basal--bolus insulin treatment regimens, which can unfortunately have high complexity and burden for patients. Importantly, the DUAL VII trial investigated the efficacy and safety of IDegLira versus basal--bolus therapy and showed non-inferior reduction in HbA~1c~, lower hypoglycemia rates, weight loss, and less treatment burden versus basal--bolus therapy in patients requiring prandial control \[[@CR5]\]. The data from the DUAL VII trial showed that basal--bolus therapy may not be the best intensification option for patients with HbA~1c~ over 7.0% (53 mmol/mol) on basal insulin \[[@CR5]\]. Conversely, the safety and efficacy of transitioning patients on a basal--bolus regimen to a fixed-ratio combination, such as IDegLira, has not been shown.

Therefore, the DUAL II Japan trial offered the opportunity for a post hoc analysis that could examine the safety and efficacy of transitioning patients from a premixed regimen (containing both basal and bolus insulin components) to IDegLira. DUAL II Japan was a 26-week, phase 3a randomized, treat-to-target trial that compared the efficacy and safety of IDegLira with degludec in 210 Japanese patients with T2D uncontrolled on basal or premixed insulin therapy \[[@CR14]\]. Results demonstrated that IDegLira was superior to degludec in terms of change from baseline in HbA~1c~ with an estimated treatment difference of − 1.28%-points \[95% CI − 1.50; − 1.06\] (− 13.98 mmol/mol \[95% CI− 16.41; − 11.55\], *P* \< 0.0001).

In order to inform on the practicality of switching patients uncontrolled on premixed insulin to IDegLira, this post hoc analysis presents efficacy and safety data, according to pre-trial insulin regimen (premixed or basal insulin), for Japanese patients who switched to IDegLira compared with those who switched to degludec.

Methods {#Sec2}
=======

This was a post hoc analysis of the DUAL II Japan trial (NCT02911948). The methodology and results of DUAL II Japan have been reported previously \[[@CR14]\]. In brief, DUAL II Japan was a 26-week randomized, two-arm, parallel, double-blinded, multicenter, treat-to-target trial that compared the efficacy and safety of IDegLira with degludec in Japanese patients with T2D \[[@CR14]\]. Patients were Japanese adults with a body mass index of at least 23 kg/m^2^, HbA~1c~ of 7.5--11.0% (58--97 mmol/mol), who were inadequately controlled with basal or premixed insulin therapy in combination with metformin with or without an oral antidiabetic drug (OAD, stable daily dose 20--50 units (U), both inclusive, for at least 60 days prior to screening) \[[@CR14]\].

Patients were stratified according to prior OAD and insulin treatment regimen \[[@CR14]\]. The recommended starting dose for both IDegLira and degludec was 10 U, with an option of increasing the starting dose up to 16 U at the investigators' discretion, based on the patient's conditions (e.g., previous insulin dose or level of glycemic control). The dose of IDegLira and degludec was titrated twice-weekly in increments of ± 2 based on the mean of three consecutive pre-breakfast self-measured blood glucose (SMBG) values aiming for a mean plasma glucose of 72 mg/dL (4.0 mmol/L) and 90 mg/dL (5.0 mmol/L). The maximum daily dose was 50 U for both degludec and IDegLira, which was also the maximum dose for IDegLira in all phase 3 trials \[[@CR3]--[@CR6], [@CR8], [@CR9], [@CR11], [@CR13], [@CR15]\].

The primary endpoint of DUAL II Japan was change from baseline in HbA~1c~ after 26 weeks. The following endpoints were assessed in this post hoc analysis by pre-trial insulin regimen: change in HbA~1c~, change in body weight, daily total insulin dose, nine-point SMBG, and severe or blood glucose-confirmed hypoglycemia. Safety parameters were also assessed. SMBG was assessed using a blood glucose meter calibrated to plasma equivalent values. Hypoglycemic events consisted of either blood glucose-confirmed symptomatic events \[plasma glucose level less than 3.1 mmol/L (56 mg/dL)\] with symptoms consistent with hypoglycemia) and/or severe episodes requiring third-party assistance. The protocol was approved by independent ethics committees or institutional review boards at all participating institutions. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Statistical Analysis {#Sec3}
--------------------

Results for the subgroup analysis assessing if results for change in HbA~1c~ were affected by pre-trial insulin regimen (i.e., premixed or basal insulin) were analyzed using an analysis of covariance (ANCOVA) model with treatment, pre-trial insulin regimen, and interaction between treatment and pre-trial insulin regimen as fixed factors, and baseline response as covariate. All other results were presented descriptively, with no formal statistical comparison performed. Missing data were imputed using last observation carried forward.

Results {#Sec4}
=======

This post hoc evaluation includes data for a subset of 39 and 38 patients who switched from premixed insulin to IDegLira and degludec, respectively; data are also presented for 66 and 67 patients who switched from basal insulin to IDegLira and degludec, respectively. No patients withdrew from the IDegLira arm. Seven patients withdrew from the degludec arm; of these, three patients switched from premixed insulin and four patients switched from basal insulin.

Demographics and baseline characteristics by pre-trial insulin regimen are shown in Table [1](#Tab1){ref-type="table"}. The subset of patients pre-treated with premixed and basal insulins had mean \[standard deviation (SD)\] HbA~1c~ at baseline of 8.26% (0.73) (66.78 mmol/mol \[7.98\]) and 8.81% (0.91) (72.79 mmol/mol \[9.95\]) in the IDegLira arm, and 8.34% (0.68) (67.65 mmol/mol \[7.43\]) and 8.69% (0.84) (71.48 mmol/mol \[9.18\]) in the degludec arm, respectively. For patients previously treated with premixed insulin, the mean duration of diabetes was 17.5 years and 16.5 years, in the IDegLira and degludec arms, respectively. For patients previously treated with basal insulin, the mean duration of diabetes was 12.5 years and 12.2 years, in the IDegLira and degludec arms, respectively.Table 1Baseline characteristics by pre-trial insulin regimenPre-trial insulin regimenPremixed insulinBasal insulinTrial insulin regimenIDegLiraDegludecIDegLiraDegludecFull analysis set39^a^38^b^6667Age, years60.2 (10.7)59.7 (8.7)54.4 (9.7)53.2 (9.9)Duration of diabetes, years17.5 (7.8)16.5 (7.5)12.5 (7.2)12.2 (7.0)Daily dose of pre-trial insulin, U14.1 (3.4)15.6 (2.6)15.2 (2.9)15.9 (3.0)Male, %69.250.065.265.7Body weight, kg71.9 (11.3)71.5 (13.4)75.1 (12.1)77.8 (13.9)BMI, kg/m^2^26.5 (2.7)27.5 (4.5)27.7 (3.3)28.4 (4.3)FPG, mmol/L9.5 (2.7)8.8 (3.0)8.6 (2.5)8.5 (2.2)FPG, mg/dL171.9 (48.9)159.3 (53.8)155.1 (45.0)153.5 (40.1)HbA~1c~, mmol/mol66.8 (8.0)67.6 (7.4)72.8 (10.0)71.4 (9.1)HbA~1c~, %8.3 (0.7)8.3 (0.7)8.8 (0.9)8.7 (0.8)Full analysis set. Data are mean (SD) values*BMI* body mass index, *degludec* insulin degludec, *FPG* fasting plasma glucose, *HbA*~*1c*~ glycated hemoglobin, *IDegLira* insulin degludec/liraglutide, *SD* standard deviation, *U* unit^a^Seven of the 39 patients in the premixed subgroup were receiving insulin degludec/insulin aspart^b^Nine of the 38 patients in the premixed subgroup were receiving insulin degludec/insulin aspart

In all subsets, mean HbA~1c~ decreased during the trial. After 26 weeks of treatment, mean HbA~1c~ in the premixed insulin subset decreased from 8.26% (0.73) (66.78 mmol/mol \[7.98\]) at baseline to 6.68% (0.93) (49.51 mmol/mol \[10.16\]) at end-of-trial (EOT) with IDegLira, and 8.34% (0.68) (67.65 mmol/mol \[7.43\]) to 8.18% (1.03) (65.90 mmol/mol \[11.26\]) with degludec (Fig. [1](#Fig1){ref-type="fig"}a). Mean HbA~1c~ in the basal insulin subset decreased from 8.81% (0.91) (72.79 mmol/mol \[9.95\]) at baseline to 6.64% (0.72) (49.07 mmol/mol \[7.87\]) at EOT with IDegLira, and 8.69% (0.84) (71.48 mmol/mol \[9.18\]) to 7.77% (1.04) (61.42 mmol/mol \[11.37\]) with degludec, after 26 weeks (Fig. [1](#Fig1){ref-type="fig"}a). The interaction between treatment and pre-trial insulin regimen was not statistically significant (premixed or basal; interaction test, *P* = 0.2535), which indicated that the treatment difference for change in HbA~1c~ was not affected by pre-trial insulin regimen.Fig. 1Mean change from baseline to week 26 in **a** HbA~1c~ (%) and **b** body weight (kg) by pre-trial insulin regimen. Data are mean values. Missing data were imputed using last observation carried forward. Degludec insulin degludec, HbA~1c~ glycated hemoglobin, IDegLira insulin degludec/liraglutide

Mean (SD) body weight was reduced in the patient subsets pre-treated with premixed and basal insulin in the IDegLira arm (− 1.5 kg \[2.9\] and − 0.3 kg \[3.7\], respectively), as compared with weight gain for the subsets in the degludec arm (+ 0.1 kg \[2.8\] and + 1.1 kg \[2.7\], respectively; Fig. [1](#Fig1){ref-type="fig"}b).

Mean daily IDegLira doses at EOT in the premixed and basal insulin subsets were 34.2 dose steps (34.2 U degludec and 1.2 mg liraglutide) and 39.6 dose steps (39.6 U degludec and 1.4 mg liraglutide) in the IDegLira arm compared with 39.4 U and 42.2 U in the degludec arm, respectively (Fig. S1 in the supplementary material).

In the subset of patients inadequately controlled with premixed insulin at baseline, the mean SMBG values decreased more with IDegLira than with degludec after 12 weeks (Fig. S2 in the supplementary material). After 26 weeks, the mean prandial increment was smaller at all meals with IDegLira irrespective of pre-trial insulin regimen (Table S1 in the supplementary material). Postprandial SMBG levels improved in all patients who switched to IDegLira (Fig. S2 in the supplementary material).

The corresponding rates for patients who experienced severe or blood glucose-confirmed hypoglycemic episodes in the premixed and basal insulin subsets were 2.59 and 2.11 episodes per patient-year of exposure (PYE) with IDegLira, compared with 3.97 and 1.04 episodes per PYE with degludec, respectively (Table S2 in the supplementary material).

The percentages of patients experiencing at least one adverse event (AE) were comparable in each treatment arm, regardless of pre-treatment regimen (Table S3 in the supplementary material). As expected with a GLP-1RA-based treatment regimen, the rate of gastrointestinal AEs was higher in the IDegLira group versus the degludec group. Three patients (2.9%) reported a total of four serious AEs (SAEs) with IDegLira compared with four patients (3.8%) reporting a total of six SAEs with degludec; details are reported in the primary analysis (Table S3 in the supplementary material) of \[[@CR14]\].

Discussion {#Sec5}
==========

This post hoc analysis represents the first study to specifically evaluate the switch to IDegLira in a subset of patients with T2D who were uncontrolled on premixed insulin plus metformin (with or without one additional OAD). This study provides insight into transitioning patients from a regimen that contains basal and bolus insulin components (premixed) to a fixed-ratio combination of a GLP-1RA and basal insulin, IDegLira. Overall, the findings showed that patients on premixed insulin can have improvements in blood glucose levels without increasing complexity, causing weight gain, or increasing rates of hypoglycemia.

Consistent with the results of the primary analysis, which demonstrated a superior change in HbA~1c~ with IDegLira versus degludec \[[@CR14]\], and regardless of pre-trial insulin regimen (premixed or basal insulin), results of this post hoc analysis demonstrated a numerically greater reduction in HbA~1c~ from baseline with IDegLira versus degludec. The results of an interaction test for change in HbA~1c~ after 26 weeks, (*P* = 0.2535) indicated that the treatment difference was not different in each of the pre-trial treatment groups.

Additional findings regarding weight change, hypoglycemia, and SMBG levels are also valuable in determining the utility of transitioning a patient from premixed insulin to IDegLira. In patients treated previously with premixed insulin there was more weight loss/less weight gain than for patients treated previously with basal insulin, irrespective of the trial treatment. The mean prandial SMBG increment across all meals was improved with IDegLira compared with patients previously treated with premixed insulin. In contrast, patients who switched from premixed insulin to degludec did not show improvements in prandial SMBG. These findings indicated that patients on premixed insulin, with a basal--bolus component, where postprandial control would be expected, had further improvements with IDegLira. Moreover, transitioning patients from premixed insulin to an optimally-titrated basal insulin did not improve the postprandial blood glucose excursion. These findings aligned with data showing that GLP-1RA treatment helped to reduce postprandial glucose excursions \[[@CR16]\]. The improvement in glycemic control observed with IDegLira was achieved with a numerically lower insulin dose than with degludec, regardless of pre-trial insulin regimen. These data show that intensifying therapy from a premixed insulin to a fixed-ratio of basal insulin and GLP-1RA is more efficacious and safe than switching to basal insulin alone. Furthermore, these data suggest that IDegLira may be an appropriate treatment choice in lieu of a more complex basal--bolus regimen in patients who have uncontrolled blood glucose on premixed insulin. In terms of safety, a higher rate of hypoglycemia was observed in patients previously treated with premixed insulin at baseline compared with basal insulin, regardless of which randomized treatment patients were receiving.

No unexpected safety or tolerability issues were observed with IDegLira in patients previously treated with premixed or basal insulin regimens, and the findings regarding a higher incidence of gastrointestinal AEs in the IDegLira group was consistent with the safety profile of liraglutide \[[@CR17]\].

In the overall study, patients were randomized to receive IDegLira and degludec; however, differences between premixed and basal insulin regimens should be interpreted with care, as patients were not randomized to pre-trial treatment. The small study population was a limitation of this analysis, and due to this, no formal statistical comparison between treatments was conducted. Nonetheless, a comparison of the efficacy data with IDegLira versus degludec indicated that the improvements observed in patients switching from premixed insulin to IDegLira was not due to an overall trial effect. This post hoc analysis offers insight into the effectiveness and safety of switching patients from premixed insulin therapy to IDegLira, and provides support for further investigation into this switch.

Conclusion {#Sec6}
==========

This post hoc analysis, the first to evaluate the switch from premixed insulin to IDegLira in patients with uncontrolled T2D, demonstrated that IDegLira initiation resulted in improved HbA~1c~, with underlying improvements of both fasting and prandial glucose and accompanied by weight loss.
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